Millennium Management LLC Purchases 263,146 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Millennium Management LLC boosted its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 50.9% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 779,672 shares of the company's stock after purchasing an additional 263,146 shares during the period. Millennium Management LLC owned about 1.08% of Kiniksa Pharmaceuticals worth $15,422,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth about $61,000. KLP Kapitalforvaltning AS bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth about $158,000. Bellevue Group AG bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter worth about $160,000. Tower Research Capital LLC TRC grew its position in Kiniksa Pharmaceuticals by 117.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after purchasing an additional 4,575 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its position in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company's stock worth $174,000 after purchasing an additional 1,004 shares in the last quarter. 53.95% of the stock is owned by institutional investors.

Analyst Ratings Changes

KNSA has been the topic of a number of research analyst reports. Jefferies Financial Group boosted their target price on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the company a "buy" rating in a research note on Tuesday, April 29th. Citigroup initiated coverage on shares of Kiniksa Pharmaceuticals in a research note on Thursday, March 13th. They issued a "buy" rating and a $40.00 target price on the stock. Finally, Wedbush reiterated an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a research note on Wednesday, April 16th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $38.80.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $25.95 on Friday. The firm's fifty day moving average price is $23.17 and its 200-day moving average price is $21.47. The stock has a market cap of $1.89 billion, a P/E ratio of -185.34 and a beta of 0.07. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $17.38 and a fifty-two week high of $28.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.09. The firm had revenue of $137.79 million for the quarter, compared to analysts' expectations of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business's quarterly revenue was up 72.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) EPS. On average, analysts predict that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Insider Activity at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,051 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $22.45, for a total value of $203,194.95. Following the sale, the chief accounting officer now owns 26,528 shares of the company's stock, valued at $595,553.60. This trade represents a 25.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ross Moat sold 23,234 shares of the firm's stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $28.02, for a total transaction of $651,016.68. Following the completion of the sale, the insider now directly owns 9,415 shares in the company, valued at approximately $263,808.30. This trade represents a 71.16% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 243,640 shares of company stock valued at $5,986,056. Insiders own 54.57% of the company's stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.